Amée Buziau

Post doc

Dr Amée Buziau obtained her master’s degree in Nutrition and Health from Wageningen University & Research. During her studies, she completed her bachelor’s internship at the Human Nutrition Unit at the University of Auckland, New Zealand, and her master’s internship at the School of Public Health at the University of Queensland, Australia. In 2018, she started her PhD research at CARIM, under the supervision of Prof. Martijn Brouwers, Prof. Casper Schalkwijk, and Prof. Coen Stehouwer. During her PhD, she focused on the role of fructose in the pathogenesis of intrahepatic lipid accumulation. To address this research question, she employed a multidisciplinary approach combining genetic epidemiology (including Mendelian randomization), nutritional epidemiology, human intervention studies, and experimental studies in mice.

In 2023, Amée was awarded the CARIM Postdoctoral Talent Fellowship, which funded the first year of her postdoctoral research at the Stem Cell Institute Leuven, Belgium, in the group of Prof. Catherine Verfaillie. During this period, she acquired expertise in generating human induced pluripotent stem cells (hiPSCs) and differentiating them into hepatocyte-like cells, with the aim of developing an in vitro model to investigate the mechanisms underlying fructose-induced intrahepatic lipid accumulation and liver metabolism.

Subsequently, she was awarded a three-year personal Junior Fellowship from the Dutch Diabetes Foundation to investigate the role of the pentose phosphate pathway in fructose-induced intrahepatic lipid accumulation. Her current research integrates hiPSC-derived hepatocytes, large-scale epidemiological studies, and human experimental studies to investigate how hepatic fructose metabolism contributes to metabolic liver disease. Her overarching aim is to elucidate the metabolic mechanisms linking fructose exposure to hepatic lipid accumulation and to identify novel biomarkers and potential therapeutic targets for metabolic dysfunction-associated steatotic liver disease (MASLD).

Department ofInternal Medicine
Universiteitssingl 60, 6229 ER Maastricht 
PO Box 616, 6200 MD Maastricht

  • 2026
    • Buziau, A. M., Simons, N., Tolan, D. R., Caiment, F., Scheijen, J. L. J. M., van de Waarenburg, M. P., Schalkwijk, C. G., & Brouwers, M. C. G. J. (2026). Endogenous fructose production in patients and mice with aldolase B deficiency. Molecular Genetics and Metabolism, 149(1-2), Article 110219. https://doi.org/10.1016/j.ymgme.2026.110219
    • Buziau, A. M., Wesselius, A., Yu, E. Y.-W., Korver-Keularts, I. M. L. W., Visser, D., Steinbusch, L. K. M., Simons, P. I. H. G., van Greevenbroek, M. M. J., Dagnelie, P. C., Kooi, M. E., Eussen, S. J. P. M., Arts, I. C. W., van der Kallen, C. J. H., Schalkwijk, C. G., & Brouwers, M. C. G. J. (2026). Metabolite Erythritol in 24-Hour Urine Is Associated With Higher Intrahepatic Lipid Content: The Maastricht Study. Diabetes, 75(5), 762-771. https://doi.org/10.2337/db25-0881
  • 2025
    • van Oeteren, M. A. J., De Groot, D. M., Buziau, A. M., Scheijen, J. L. J. M., van de Waarenburg, M. P. H., Kroon, A. A., Eussen, S. J. P. M., Dagnelie, P. C., Van Greevenbroek, M. M. J., Houben, A. J. H. M., Meex, S. J. R., Schalkwijk, C. G., & Brouwers, M. C. G. J. (2025). The effects of dietary fructose on blood pressure are modified by the food matrix. Clinical Nutrition, 55, 134-140. https://doi.org/10.1016/j.clnu.2025.10.017
    • Koene, E. J., Buziau, A. M., Cassiman, D., Cox, T. M., Bons, J., Scheijen, J. L. J. M., Schalkwijk, C. G., Meex, S. J., Saxena, A. R., Esler, W. P., Schrauwen-Hinderling, V. B., Schrauwen, P., & Brouwers, M. C. (2025). Safety and efficacy of pharmacological inhibition of ketohexokinase in hereditary fructose intolerance. Journal of Clinical Investigation, 135(6), Article e187376. https://doi.org/10.1172/JCI187376
    • Buziau, A. M., Lefeber, D. J., Cassiman, D., Rubio-Gozalbo, M. E., Kwast, H., Tolan, D. R., Schalkwijk, C. G., & Brouwers, M. C. G. J. (2025). Aldolase B Deficient Mice Are Characterized by Hepatic Nucleotide Sugar Abnormalities. Journal of Inherited Metabolic Disease, 48(1), Article e12836. https://doi.org/10.1002/jimd.12836
  • 2024
    • Buziau, A. M., Oosterveer, M. H., Wouters, K., Bos, T., Tolan, D. R., Agius, L., Ford, B. E., Cassiman, D., Stehouwer, C. D. A., Schalkwijk, C. G., & Brouwers, M. C. G. J. (2024). Hepatic glucokinase regulatory protein and carbohydrate response element binding protein attenuation reduce de novo lipogenesis but do not mitigate intrahepatic triglyceride accumulation in ALDOB deficiency. Molecular Metabolism, 87, Article 101984. https://doi.org/10.1016/j.molmet.2024.101984
    • Chen, H., Buziau, A. M., Renteria, M. E., Simons, P. I. H. G., & Brouwers, M. C. G. J. (2024). Fructose intake from sugar-sweetened beverages is associated with a greater risk of hyperandrogenism in women: UK Biobank cohort study. European Journal of Endocrinology, 190(1), 104-112. https://doi.org/10.1093/ejendo/lvae006
  • 2023
    • Buziau, A. M., Scheijen, J. L. J. M., Stehouwer, C. D. A., Schalkwijk, C. G., & Brouwers, M. C. G. J. (2023). Effects of fructose added to an oral glucose tolerance test on plasma glucose excursions in healthy adults. Metabolism open, 18(1), Article 100245. https://doi.org/10.1016/j.metop.2023.100245
    • Buziau, A. M., Blokland, G. A. M., Schalkwijk, C. G., Scheijen, J. L. J. M., Simons, P. I. H. G., Eussen, S. J. P. M., Dagnelie, P. C., van Greevenbroek, M. M. J., Wesselius, A., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2023). Comment on Lee et al. Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies. Diabetes Care 2022;45. Diabetes Care, 46(4), E97-E98. https://doi.org/10.2337/dc22-1930
    • Buziau, A. M., Law, P. J., Blokland, G., Schalkwijk, C., Scheijen, J., Simons, P., van der Kallen, C., Eussen, S., Dagnelie, P. C., van Greevenbroek, M., Houlston, R. S., Wesselius, A., Went, M., Stehouwer, C., & Brouwers, M. C. (2023). Genetically proxied ketohexokinase function and risk of colorectal cancer: a Mendelian randomisation study. Gut, 72(3), 604-606. https://doi.org/10.1136/gutjnl-2021-326299